Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor

David A Perrey1, Nadezhda A German, Brian P Gilmour

  • 1Research Triangle Institute , Research Triangle Park, North Carolina 27709, United States.

Insights

Selective OX1 receptor antagonists may treat drug addiction. Researchers developed novel tetrahydroisoquinoline compounds, with Compound 72 showing promise by reducing cocaine-induced place preference in rats, indicating therapeutic potential.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • The orexin 1 (OX1) receptor is increasingly implicated in reward pathways.
  • OX1 receptor antagonism presents a potential therapeutic strategy for substance use disorders.

Purpose of the Study:

  • To design and synthesize novel OX1 selective antagonists.
  • To investigate the structure-activity relationships (SAR) of tetrahydroisoquinoline derivatives for OX1 antagonism.
  • To evaluate the efficacy of a lead compound in a preclinical model of drug addiction.

Main Methods:

  • Synthesis of substituted tetrahydroisoquinoline compounds.
  • In vitro evaluation using OX1 and OX2 calcium mobilization assays.
  • Structure-activity relationship (SAR) analysis and computational modeling.
  • In vivo assessment of cocaine-induced place preference in a rat model.

Main Results:

  • SAR studies identified key structural requirements for OX1 receptor antagonism, including limited steric tolerance and electron deficiency at the 7-position.
  • Pyridylmethyl groups at the acetamide position were optimal for activity.
  • A pharmacophore model was developed, consistent with SAR findings.
  • Compound 72 demonstrated significant attenuation of cocaine-induced place preference in rats.

Conclusions:

  • Novel tetrahydroisoquinoline derivatives were successfully designed and synthesized as selective OX1 antagonists.
  • Compound 72 exhibits preclinical efficacy in a cocaine addiction model.
  • These findings support the development of OX1 antagonists as a potential treatment for drug addiction.

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...